Lupin has entered into distribution agreement with three companies for its orphan drug NaMuscla (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain EU territories. NaMuscula is the first and only licensed product for this indication.
NDM disorders are a group of rare, inherited neuromuscular disorders which cause the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional and clinical outcomes. NaMuscla, which has been designated orphan drug status, received EU marketing authorization in December 2018.
Under the agreements, Exeltis Healthcare S.L will commercialize NaMuscla in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla in the Netherlands and Macure Pharma ApS in the Nordic countries. The company will continue commercialization of NaMuscla in Germany and UK and will launch the product in Austria and France later this year.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.